Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€18.22

€18.22

-0.440%
-0.08
-0.440%
-
 
07.11.25 / Tradegate WKN: A3ENQ5 / Name: Schott Pharma & Co. Kgaa / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Schott Pharma & Co. Kgaa

sharewise wants to provide you with the best news and tools for Schott Pharma & Co. Kgaa, so we directly link to the best financial data sources.

News

EQS-News: SCHOTT Pharma: Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma
EQS-News: SCHOTT Pharma: Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma
EQS-News: SCHOTT Pharma: Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Christian Mias to succeed Andreas Reisse as CEO
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Christian Mias to succeed Andreas Reisse as CEO
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Christian Mias to succeed Andreas Reisse as CEO
EQS-News: SCHOTT Pharma delivers solid final third-quarter results
EQS-News: SCHOTT Pharma delivers solid final third-quarter results
EQS-News: SCHOTT Pharma delivers solid final third-quarter results
EQS-News: SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
EQS-News: SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
EQS-News: SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
EQS-News: SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO
EQS-News: SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO
EQS-News: SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO
EQS-News: SCHOTT Pharma invests in sterile cartridge production in Hungary
EQS-News: SCHOTT Pharma invests in sterile cartridge production in Hungary
EQS-News: SCHOTT Pharma invests in sterile cartridge production in Hungary
EQS-News: SCHOTT Pharma delivers strong second quarter of fiscal year 2025
EQS-News: SCHOTT Pharma delivers strong second quarter of fiscal year 2025
EQS-News: SCHOTT Pharma delivers strong second quarter of fiscal year 2025